CF
TRML

Corebridge Financial’s Tourmaline Bio TRML Stock Holding History

Corebridge Financial’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,309
Closed -$172K – 2576
2025
Q1 		$172K Sell
11,309
-168
-1% -$2.69K ﹤0.01% 2158
2024
Q4 		$233K Sell
11,477
-866
-7% -$21.8K ﹤0.01% 2090
2024
Q3 		$317K Sell
12,343
-76
-0.6% -$1.27K ﹤0.01% 1965
2024
Q2 		$160K Buy
+12,419
New +$200K ﹤0.01% 2335

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Corebridge Financial's TRML Position: Q2 2025 in Review

Corebridge Financial sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 11,309 shares — an estimated $172K sold.

Corebridge Financial first reported a position in TRML in Q2 2024 and held it in 4 quarters. The position peaked at $317K in Q3 2024. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • Corebridge Financial reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 11,309 Tourmaline Bio shares in Q2 2025, an estimated $172K.
  • Corebridge Financial first reported a position in Tourmaline Bio in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Tourmaline Bio position peaked at $317K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.